Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions

Molecular Cancer Therapeutics

Volumn 8, Issue 3, 2009, Pages 552-562

  Gopal, Y N Vashisht ^a   Chanchorn, Ekkawit ^a   Van Dyke, Michael W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; NUTLIN 3; PARTHENOLIDE; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; ANTINEOPLASTIC AGENT; HDAC1 PROTEIN, HUMAN; HISTONE DEACETYLASE; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; SESQUITERPENE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG STRUCTURE; GENE DELETION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; UBIQUITINATION; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL STRAIN HCT116; DRUG ANTAGONISM; DRUG EFFECT; GENETIC TRANSCRIPTION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; PROTEIN PROCESSING; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; IMIDAZOLES; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; SESQUITERPENES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UP-REGULATION;

EID: 66449097674     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0661     Document Type: Article

References (48)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331 (Pubitemid 27131374)
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310
3. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. MDM2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-8951 (Pubitemid 30180252)
4. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono- versus polyubiquitination: differential control of p53 fate by MDM2. Science 2003;302:1972-1975 (Pubitemid 37523506)
5. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300. (Pubitemid 30106484)
6. Saito S, Goodarzi AA, Higashimoto Y, et al. ATM mediates phosphorylation at multiple p53 sites, including Ser46, in response to ionizing radiation. J Biol Chem 2002;277:12 491-494 (Pubitemid 34952604)
7. Liu L, Scolnick DM, Trievel RC, et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999;19:1202-1209 (Pubitemid 29046862)
8. Ito A, Kawaguchi Y, Lai CH, et al. MDM2-1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236-6245 (Pubitemid 35415340)
9. Wang C, Ivanov A, Chen L, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 2005;24:3279-3290 (Pubitemid 41348702)
10. Fontana X, Ferrari P, Abbes M, Monticelli J, Namer M, Bussiere F. Study of MDM2 gene amplification in primary breast tumors. Bull Cancer 1994;81:587-592 (Pubitemid 24231212)
11. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459 (Pubitemid 28347214)
12. Arora S, Mathew R, Mathur M, Chattopadhayay TK, Ralhan R. Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status. Pathol Oncol Res 2001;7:203-208 (Pubitemid 33716856)
13. Koga T, Hashimoto S, Sugio K, et al. Heterogeneous distribution of p53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with p53 gene mutation. Int J Cancer 2001;95:232-239 (Pubitemid 32592090)
14. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-18 (Pubitemid 23019370)
15. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Transition from in situ to invasive testicular germcell neoplasia is associated with the loss of p21 and gain of MDM-2 expression. Mod Pathol 2001;14:437-442 (Pubitemid 32448742)
16. Mathew R, Arora S, Khanna R, Mathur M, Shukla NK, Ralhan R. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur J Cancer 2002;38:832-841 (Pubitemid 34280330)
17. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41. (Pubitemid 40321798)
18. Ganguli G, Wasylyk B. p53-independent functions of MDM2. Mol Cancer Res 2003;1:1027-1035
19. Yang JY, Zong CS, Xia W, et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006;26:7269-7282 (Pubitemid 44477702)
20. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2002;2:442-454 (Pubitemid 37328941)
21. Lai Z, Yang T, Kim YB, et al. Differentiation of HDM2-mediated p53 ubiquitination and HDM2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci USA 2002;99:14734-14739 (Pubitemid 35334553)
22. Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005;7:47-59. (Pubitemid 40799248)
23. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848
24. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007;26:3473-3481 (Pubitemid 46816754)
25. Siedle B, Garcia-Pineres AJ, Murillo R, et al. Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-κB. J Med Chem 2004;47:604 2-54. (Pubitemid 39507346)
26. Da Costa FB, Terfloth L, Gasteiger J. Sesquiterpene lactone-based classification of three Asteraceae tribes: a study based on self-organizing neural networks applied to chemosystematics. Phytochemistry 2005;66:345-353 (Pubitemid 40169994)
27. Knight DW. Feverfew: chemistry and biological activity. Nat Prod Rep 1995;12:271-276
28. Curry EA, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22:299-305. (Pubitemid 39012569)
29. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM. Suppressed NF-κB, sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-α-induced apoptosis in human cancer cells. Carcinogenesis 2004;25:2191-2199 (Pubitemid 39534857)
30. Hehner SP, Hofmann TG, Droge W, Schmitz ML. The anti-inflammatory sesquiterpene lactone parthenolide inhibits NF-κB by targeting the IκB kinase complex. J Immunol 1999;163:5617-5623
31. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000;19:4159-4169
32. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IκB kinase. Chem Biol 2001;8:759-766 (Pubitemid 32752455)
33. Nakshatri H, Rice SE, Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330-7344 (Pubitemid 39382136)
34. Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005;105:4163-4169 (Pubitemid 40720758)
35. Guzman ML, Rossi RM, Neelakantan S, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-4435
36. Vashisht Gopal YN, Arora TS, Van Dyke MW. Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 2007;14:813-823 (Pubitemid 47081425)
37. Vashisht Gopal YN, Arora TS, Van Dyke MW. Tumor necrosis factor-α depletes histone deacetylase I protein through IKK2. EMBO Rep 2006;42:6891-6903
38. Vashisht Gopal YN, Van Dyke MW. Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling? Cell Cycle 2006;5:2738-2743
39. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825 (Pubitemid 23346378)
40. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-682 (Pubitemid 32706358)
41. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-899 (Pubitemid 20192074)
42. Barak Y, Juven T, Haffner R, Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-468 (Pubitemid 23073692)
43. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001;268:2764-2772 (Pubitemid 32862957)
44. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-694 (Pubitemid 32706359)
45. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2006;15:2177-2196
46. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999;96:14973-14977 (Pubitemid 30019749)
47. Maya R, Balass M, Kim ST, et al. ATM-dependent phosphorylation of MDM2 on serine 395: role in p53 activation by DNA damage. Genes Dev 2001;15:1067-1077 (Pubitemid 32417300)
48. de Rozieres S, Maya R, Oren M, Lozano G. The loss of MDM2 induces p53 mediated apoptosis. Oncogene 2000;19:1691-1697 (Pubitemid 30200971)